back to

ISHL9 Videos

Overview of international harmonization of staging and response criteria in pediatric Hodgkin Lymphoma – summary of results thus far

Overview of international harmonization of staging and response criteria in pediatric Hodgkin Lymphoma – summary of results thus far

Monika Metzger

Closing comments

Closing comments

Andreas Engert

Microenvironment in Hodgkin Lymphoma

Microenvironment in Hodgkin Lymphoma

Randy Gascoyne

Plasma microRNA are disease response biomarkers in classical Hodgkin Lymphoma

Plasma microRNA are disease response biomarkers in classical Hodgkin Lymphoma

Kimberley Jones

CD57+ T cells in nodular lymphocyte predominant Hodgkin Lymphoma are
T-follicular helper cells

CD57+ T cells in nodular lymphocyte predominant Hodgkin Lymphoma are T-follicular helper cells

Ahmad Sattarzadeh

Update on the NCRI RAPID trial

Update on the NCRI RAPID trial

John Radford

An update on the EORTC / LYSA / FIL H10 trial

An update on the EORTC / LYSA / FIL H10 trial

Marc André

WS report and further optimization in early stage Hodgkin Lymphoma

WS report and further optimization in early stage Hodgkin Lymphoma

Andreas Engert

Impact of bleomycin and dacarbazine within the ABVD regimen in the treatment of early-stage favorable Hodgkin Lymphoma: Final results of the GHSG HD13 trial

Impact of bleomycin and dacarbazine within the ABVD regimen in the treatment of early-stage favorable Hodgkin Lymphoma: Final results of the GHSG HD13 trial

Karolin Behringer

De nition of bulky disease in early stage Hodgkin Lymphoma in computed tomography era: Prognostic signi cance of measurements in the coronal and transverse planes

De nition of bulky disease in early stage Hodgkin Lymphoma in computed tomography era: Prognostic signi cance of measurements in the coronal and transverse planes

Anita Kumar

First line treatment

First line treatment

Stephen J. Proctor

$Relapsed / refractory Hodgkin Lymphoma in older patients$

Relapsed / refractory Hodgkin Lymphoma in older patients

Boris Böll

GHSH phase I / II trial of AVD-Rev (adriamycin, vinblastin, dacarbacine and lenalidomide) for older Hodgkin Lymphoma patients

GHSH phase I / II trial of AVD-Rev (adriamycin, vinblastin, dacarbacine and lenalidomide) for older Hodgkin Lymphoma patients

Boris Böll

Treatment outcome in 111 elderly patients with Hodgkin Lymphoma: a retrospective analysis

Treatment outcome in 111 elderly patients with Hodgkin Lymphoma: a retrospective analysis

Aspasia Stamatoullas

PET for early response prediction

PET for early response prediction

Martin Hutchings

PET review in GHSG trials

PET review in GHSG trials

Markus Dietlein

Very early response as measured by (18F)- uorodeoxyglucose-positron emission tomography (FDG-PET) a er one cycle of chemotherapy in newly diagnosed pediatric / adolescent low risk Hodgkin Lymphoma (HL)

Very early response as measured by (18F)- uorodeoxyglucose-positron emission tomography (FDG-PET) a er one cycle of chemotherapy in newly diagnosed pediatric / adolescent low risk Hodgkin Lymphoma (HL)

Frank G. Keller

Practical experience in the application of the International Harmonization Criteria – as viewed by a medical oncologist

Practical experience in the application of the International Harmonization Criteria – as viewed by a medical oncologist

Anas Younes

Nuclear medicine aspects of the International Harmonization Criteria, as they apply to pediatrics

Nuclear medicine aspects of the International Harmonization Criteria, as they apply to pediatrics

Regine Kluge

Cardiac toxicity

Cardiac toxicity

Judith Landman-Parker

Breast Cancer and other Neoplasms

Breast Cancer and other Neoplasms

Berthe Aleman

Changes in breast cancer risk as long-term Hodgkin Lymphoma survivors reach menopausal age

Changes in breast cancer risk as long-term Hodgkin Lymphoma survivors reach menopausal age

Julia S. Wong

A Dutch nationwide survivorship care programme for Hodgkin Lymphoma survivors

A Dutch nationwide survivorship care programme for Hodgkin Lymphoma survivors

Flora van Leeuwen

Risk-adapted therapy in advanced stage Hodgkin Lymphoma: An Update

Risk-adapted therapy in advanced stage Hodgkin Lymphoma: An Update

Massimo Federico

Can we improve ABVD?

Can we improve ABVD?

Stephen Ansell

Impact of dose reductions of bleomycin and vincristine in patients with advanced Hodgkin Lymphoma treated with BEACOPP polychemotherapy:
A comprehensive analysis of the German Hodgkin Study Group (GHSG) HD12 and HD15 trials

Impact of dose reductions of bleomycin and vincristine in patients with advanced Hodgkin Lymphoma treated with BEACOPP polychemotherapy: A comprehensive analysis of the German Hodgkin Study Group (GHSG) HD12 and HD15 trials

Bastian von Tresckow

Standard ABVD vs. escalated BEACOPP in stage III – IV low risk Hodgkin Lymphoma (IPS 0-2): the Lymphoma Study Association (LYSA) H34 trial

Standard ABVD vs. escalated BEACOPP in stage III – IV low risk Hodgkin Lymphoma (IPS 0-2): the Lymphoma Study Association (LYSA) H34 trial

Nicolas Mounier

What’s new in relapsed Hodgkin Lymphoma?

What’s new in relapsed Hodgkin Lymphoma?

Bastian von Tresckow

Debate: Is there still a role for allogeneic
TX in Hodgkin Lymphoma?

Debate: Is there still a role for allogeneic TX in Hodgkin Lymphoma?

Patrice Carde, Karl Peggs, Anton Hagenbeek

$PET adapted sequential salvage therapy with brentuximab vedotin and augmented ICE for transplant eligible patients with relapsed and refractory Hodgkin Lymphoma$

PET adapted sequential salvage therapy with brentuximab vedotin and augmented ICE for transplant eligible patients with relapsed and refractory Hodgkin Lymphoma

Alison Moskowitz

Pathology

Pathology

Harald Stein

Prognostic indices and PET

Prognostic indices and PET

Bruce Cheson

Radiotherapy

Radiotherapy

Richard Hoppe

New drugs

New drugs

Anas Younes

Archive

You a viewing the videos of a past symposium. Click here to get back to the current conference.

The videos have been recorded by The Informed Scientist.